1-20 of 84
Amy S. Ruppert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Jonathon B. Cohen, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y. Cheah, Toby A. Eyre, Chaitra S Ujjani, Youngil Koh, Won Seog Kim, Sunita D. Nasta, Ian W. Flinn, Benoit Tessoulin, Shuo Ma, Alvaro J. Alencar, David Lewis, Jennifer A. Woyach, Kami J. Maddocks, Krish Patel, Yucai Wang, Joanna M. Rhodes, Constantine S. Tam, John F. Seymour, Hirokazu Nagai, Julie M. Vose, Bita Fakhri, Marc S. Hoffmann, Francisco J. Hernandez-Ilizaliturri, Andrew D. Zelenetz, Anita Kumar, Talha Munir, Donald E. Tsai, Minna Balbas, Bin Liu, Amy S. Ruppert, Bastien Nguyen, Lindsey E. Roeker, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 981.
https://doi.org/10.1182/blood-2023-181627
Published: 2023
Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

William G. Wierda, Nirav N. Shah, Chan Yoon Cheah, David Lewis, Marc S. Hoffmann, Catherine C. Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A. Eyre, Joanna M. Rhodes, Matthew McKinney, Ewa Lech-Maranda, Constantine S. Tam, Wojciech Jurczak, Koji Izutsu, Alvaro J. Alencar, Manish Patel, John F. Seymour, Jennifer A. Woyach, Lindsey E. Roeker, Philip A. Thompson, Paolo Abada, Caleb Ho, Narasimha Marella, Chunxiao Wang, Amy S. Ruppert, Binoj Chandrasekharan Nair, Hui Liu, Donald E. Tsai, Paolo Ghia
Journal: Blood
Blood (2023) 142 (Supplement 1): 1737.
https://doi.org/10.1182/blood-2023-181108
Published: 2023
Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Benoit Tessoulin, Nirav N. Shah, Chaitra S Ujjani, Bita Fakhri, Catherine C. Coombs, Ian W. Flinn, Manish Patel, Sunita D. Nasta, Jonathon B. Cohen, Alvaro J. Alencar, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Osterborg, Koji Izutsu, Donald E. Tsai, Paolo Abada, Minna Balbas, Jian Li, Amy S. Ruppert, Wojciech Jurczak, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 325.
https://doi.org/10.1182/blood-2023-185852
Published: 2023
Journal Articles

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Nirav N. Shah, Michael L. Wang, Jennifer R. Brown, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Zinzani, Alvaro J. Alencar, Thomas Gastinne, Paolo Ghia, Nicole Lamanna, Marc Hoffmann, Manish R. Patel, Ian W. Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Marańda, Bita Fakhri, Won-Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Lindsey E. Roeker, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4127–4132.
https://doi.org/10.1182/blood-2022-159035
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

M.Lia Palomba, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David John Lewis, Thomas Gastinne, Shuo Ma, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Lydia Scarfò, Talha Munir, Ewa Lech-Marańda, Marc Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael L. Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna M. Rhodes, Julie M. Vose, Matthew McKinney, James N. Gerson, Minal A. Barve, Bryone J. Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah
Journal: Blood
Blood (2022) 140 (Supplement 1): 557–560.
https://doi.org/10.1182/blood-2022-159123
Published: 2022
Journal Articles

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Clinical Trials & Observations
Adam S. Kittai, Cecelia Miller, Daniel Goldstein, Ying Huang, Lynne V. Abruzzo, Kyle Beckwith, Seema A. Bhat, David A. Bond, Michael R. Grever, Nyla A. Heerema, Kerry A. Rogers, Amy S. Ruppert, John C. Byrd, Jennifer A. Woyach
Journal: Blood
Blood (2021) 138 (23): 2372–2382.
https://doi.org/10.1182/blood.2020010536
Published: 2021
Includes: Supplemental data
Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Prapti Patel, Amy S. Ruppert, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Michael M. Boyiadzis, Ronan Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley Owen Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Alice S. Mims
Journal: Blood
Blood (2021) 138 (Supplement 1): 875.
https://doi.org/10.1182/blood-2021-149115
Published: 2021
Journal Articles

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric D. Hsi, Richard F. Little, Steven D. Gore, Anusha Vallurupalli, Daniel J Landsburg, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard
Journal: Blood
Blood (2021) 138 (Supplement 1): 523.
https://doi.org/10.1182/blood-2021-151266
Published: 2021
Journal Articles

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial

Inhye E. Ahn, Amy S. Ruppert, Adrian Wiestner, James S. Blachly, John C. Byrd, Richard M. Stone, Sumithra J Mandrekar, Jennifer A. Woyach
Journal: Blood
Blood (2021) 138 (Supplement 1): 2642.
https://doi.org/10.1182/blood-2021-153822
Published: 2021
Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis
Journal: Blood
Blood (2021) 138 (Supplement 1): 1279.
https://doi.org/10.1182/blood-2021-151234
Published: 2021
Journal Articles

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison M Booth, Diane Feldman, Elie G Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla A. Heerema, Cecelia Miller, Gerard Lozanski, Richard F. Little, Brian T. Hill, Wei Ding, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 3728.
https://doi.org/10.1182/blood-2021-151471
Published: 2021
Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 639.
https://doi.org/10.1182/blood-2021-153146
Published: 2021
Journal Articles

Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

Cecelia Miller, Ying Huang, Jonathan Hyak, Matthew R Avenarius, Amy S. Ruppert, John C. Byrd, Seema A Bhat, Michael R Grever, Adam S Kittai, Kerry Rogers, Nyla A. Heerema, Lynne V. Abruzzo, Jennifer A. Woyach
Journal: Blood
Blood (2021) 138 (Supplement 1): 1563.
https://doi.org/10.1182/blood-2021-150722
Published: 2021
Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Clinical Trials & Observations
Kerry A. Rogers, Leslie A. Andritsos, Lai Wei, Eric M. McLaughlin, Amy S. Ruppert, Mirela Anghelina, James S. Blachly, Timothy Call, Dai Chihara, Anees Dauki, Ling Guo, S. Percy Ivy, Lacey R. James, Daniel Jones, Robert J. Kreitman, Gerard Lozanski, David M. Lucas, Apollinaire Ngankeu, Mitch Phelps, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Jeffrey A. Jones, Michael R. Grever
Journal: Blood
Blood (2021) 137 (25): 3473–3483.
https://doi.org/10.1182/blood.2020009688
Published: 2021
Includes: Supplemental data
Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-138612
Published: 2020
Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Matthew C. Cheung, MDMSc, Nicole Mittmann, PhD, Carolyn Owen, MDFRCPC, Nizar Abdel-Samad, MD, Graeme Fraser, Selay Lam, MDBSc,FRCPC, Michael Crump, MD, Catherine Sperlich, Richard van der Jagt, Stephen Couban, MDBSc, Jennifer A. Woyach, MD, Amy S. Ruppert, PhD, Allison M Booth, Sumithra J Mandrekar, PhD, Gail T. McDonald, Lois E. Shepherd, Anca Prica, MD, Hope Yen, Bingshu E. Chen, Annette E. Hay
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–30.
https://doi.org/10.1182/blood-2020-136692
Published: 2020
Journal Articles

Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]

Amy S. Ruppert, PhD, Levi D. Pederson, MS, Michael V. Knopp, MD PhD, David Poon, BS, Jun Zhang, PhD, Brad S. Kahl, MD, Jonathan W. Friedberg, MD MSSc, Lawrence H. Schwartz, MD, Wyndham H. Wilson, MD PhD, John P. Leonard, MD, Nancy L. Bartlett, MD, Heiko Schöder, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50.
https://doi.org/10.1182/blood-2020-139979
Published: 2020
Journal Articles

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Daniel Goldstein, MD, Kyle A. Beckwith, MDPhD, Cecelia Miller, PhD, Ying Huang, MS, MA, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, David A. Bond, MD, John C. Byrd, MD, Michael R. Grever, MD, Nyla A Heerema, PhD, Kerry A. Rogers, MD, Amy S. Ruppert, PhD, Jennifer A. Woyach, MD, Adam S. Kittai, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136714
Published: 2020
Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-137655
Published: 2020